ProvideGx® Partners with Apotex Corp. to Stabilize Supply of Three Vital Antibiotics
Premier Inc. (NASDAQ: PINC) has announced a partnership with Apotex Corp. to supply three vital antibiotics: cefazolin, cefepime, and ceftriaxone. These medications are essential for treating various bacterial infections and have faced supply challenges. The collaboration aims to alleviate shortages, improve market competition, and promote stable pricing. Premier’s ProvideGx program ensures long-term commitments with manufacturers, facilitating increased production of critical drugs. The financial specifics of the agreement remain undisclosed.
- Partnership with Apotex Corp. to supply essential antibiotics.
- Enhances drug supply stability and market competition.
- ProvideGx program secures long-term contracts, promoting increased production.
- Cefazolin and cefepime have been on the FDA's drug shortage list since 2018 and 2015 respectively.
Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Apotex Corp. to supply three essential antibiotics to healthcare providers, helping to secure the immediate and long-term supply needs of a category of medications vital to treating bacterial infections.
The three medicines include cefazolin, cefepime and ceftriaxone for injection and are part of the cephalosporin category of antibiotics. Cephalosporins are one of the most widely prescribed classes of medications in the world and treat a variety of bacterial infections including skin or ear infections, strep throat, meningitis and pneumonia.
These drugs have historically experienced supply volatility in both active pharmaceutical ingredient (API) and finished manufactured product. Cefazolin and cefepime have been on and off the U.S. Food and Drug Administration’s (FDA) drug shortage list since 2018 and 2015, respectively. In the absence of these front-line antibiotics, healthcare providers are often forced to use novel antibiotics that would otherwise be reserved for severe cases thereby potentially proliferating antimicrobial resistance.
“Through our partnership with Apotex, we are taking one more step to eliminate drug shortages for our healthcare provider members, create increased market competition and promote more predictable, long-term prices,” said Premier President and incoming CEO Michael J. Alkire. “ProvideGx is building a more diversified pharmaceutical market designed to create a sustainable supply of these antibiotics commonly used for routine patient care.”
Guided by health systems with more than 1,600 hospitals across the nation, Premier’s ProvideGx program creates long-term committed buying contracts that provide participating manufacturers with the surety needed to increase production or move into new markets. Premier’s programs, including ProvideGx, currently provide members access to more than 150 drugs that are or have been recently designated as shortage drugs, with a pipeline of more than 50 additional drugs. The program also monitors weekly fill rates for more than 250 drugs necessary for COVID-19 care, provides an adequate safety stock of medicines and has successfully protected supply even as demand surged more than 150 percent during the pandemic.
“Sourcing these essential medications has been an ongoing challenge,” said Gary Kerr, Chief Pharmacy Officer at Baystate Health, a Premier member hospital system based in Springfield, Massachusetts. “These basic, life-sustaining therapies are crucial to our ability to deliver evidence-based care and improve patient outcomes. The unique ProvideGx model takes innovative steps to ensure continuous supply of shortage drugs and build greater supply chain resiliency.”
Apotex Corp. is a global pharmaceutical company that produces high-quality, affordable medicines (both generic and innovative pharmaceuticals) for patients around the world. The agreement with Premier helps facilitate increased access to these medicines for Premier member institutions and their patients.
“Apotex recognizes the importance of ensuring the continued availability and affordability of commonly used, high-quality medicines for healthcare providers and patients,” said Michael Bohling, Vice President, Sales & Marketing at Apotex Corp. “This agreement with Premier continues to build on our efforts, which we hope will ultimately increase patient access to three critical antibiotics, cefazolin, cefepime and ceftriaxone ─ helping to ensure market sustainability over the long term.”
The financial terms of Premier’s agreement with Apotex Corp. are not being disclosed.
Forward-Looking Statements Matters discussed in this release that are not statements of historical or current facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Premier to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Premier’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Premier’s control. More information on potential factors that could affect Premier’s financial results is included from time to time in the “Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Premier’s periodic and current filings with the SEC and available on Premier’s website at investors.premierinc.com. Forward-looking statements speak only as of the date they are made. Premier undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date.
About Premier, Inc.
Premier, Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,100 U.S. hospitals and health systems and approximately 200,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005232/en/
FAQ
What is the recent partnership between Premier Inc. and Apotex Corp. about?
How will the partnership impact the supply of antibiotics?
What is the significance of the ProvideGx program?
Have the antibiotics in the partnership faced shortages?
What financial details were disclosed about the agreement?
